1. Home
  2. NNY vs PYXS Comparison

NNY vs PYXS Comparison

Compare NNY & PYXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nuveen New York Municipal Value Fund

NNY

Nuveen New York Municipal Value Fund

HOLD

Current Price

$7.85

Market Cap

154.3M

Sector

Finance

ML Signal

HOLD

Logo Pyxis Oncology Inc.

PYXS

Pyxis Oncology Inc.

HOLD

Current Price

$3.35

Market Cap

141.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NNY
PYXS
Founded
1987
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
154.3M
141.3M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
NNY
PYXS
Price
$7.85
$3.35
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
$7.00
AVG Volume (30 Days)
53.8K
848.7K
Earning Date
01-01-0001
05-13-2026
Dividend Yield
4.04%
N/A
EPS Growth
N/A
3.03
EPS
N/A
N/A
Revenue
N/A
$13,858,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$7,043.98
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$7.75
$1.03
52 Week High
$8.94
$5.55

Technical Indicators

Market Signals
Indicator
NNY
PYXS
Relative Strength Index (RSI) 25.47 52.01
Support Level N/A $2.95
Resistance Level $8.81 $3.45
Average True Range (ATR) 0.08 0.32
MACD -0.02 -0.03
Stochastic Oscillator 15.89 29.86

Price Performance

Historical Comparison
NNY
PYXS

About NNY Nuveen New York Municipal Value Fund

Nuveen New York Municipal Value Fund Inc. is a diversified closed-end management investment company. The Fund seeks to provide current income exempt from regular federal, New York State, and New York City income taxes, and from the federal alternative minimum tax for individuals, while enhancing portfolio value relative to the municipal bond market by investing in tax-exempt municipal bonds considered underrated, undervalued, or from undervalued municipal market sectors. It may invest in municipal securities such as lease obligations and certificates of participation, which provide an undivided interest in pools of municipal leases or installment purchase agreements.

About PYXS Pyxis Oncology Inc.

Pyxis Oncology Inc is a clinical-stage oncology company focused on developing therapies for patients with solid tumors, with an initial emphasis on head and neck squamous cell carcinoma. Its product candidate, micvotabart pelidotin (MICVO, formerly PYX-201), is an investigational antibody-drug conjugate that targets extradomain-B fibronectin (EDB+FN), a component of the tumor extracellular matrix that is expressed in tumors and minimally present in normal tissues. MICVO consists of a fully human monoclonal antibody linked to a microtubule inhibitor payload, designed to bind within the tumor microenvironment and release its payload to kill cancer cells directly, affect nearby cells through a bystander effect, and induce immunogenic cell death, supporting enhanced anti-tumor activity.

Share on Social Networks: